NICE clears Pierre Fabre's targeted melanoma combo to take on Novartis, Roche drugs
Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some fresh targeted melanoma competition from French pharma lab Pierre Fabre. In guidance published Friday, England’s National Institute for Health and Care Excellence signed off on Pierre Fabre’s combo of Braftovi and Mektovi to treat adult patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.… Read More »